Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast CancerReportar como inadecuado




Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Annals of Surgical Oncology

, Volume 23, Issue 1, pp 51–57

First Online: 16 May 2015Received: 24 February 2015DOI: 10.1245-s10434-015-4603-3

Cite this article as: Truin, W., Vugts, G., Roumen, R.M.H. et al. Ann Surg Oncol 2016 23: 51. doi:10.1245-s10434-015-4603-3

Abstract

BackgroundThis study was conducted to determine the impact of neoadjuvant chemotherapy NAC on the likelihood of breast-conserving surgery BCS performed for patients with invasive lobular breast carcinoma ILC and invasive ductal carcinoma IDC.

MethodsFemale patients with a diagnosis of ILC or IDC in The Netherlands between July 2008 and December 2012 were identified through the population-based Netherlands Cancer Registry.

ResultsA total of 466 ILC patients received NAC compared with 3622 IDC patients. Downstaging by NAC was seen in 49.7 % of the patients with ILC and in 69.6 % of the patients with IDC, and a pathologic complete response pCR was observed in 4.9 and 20.2 % of these patients, respectively P < 0.0001. Breast-conserving surgery was performed for 24.4 % of the patients with ILC receiving NAC versus 39.4 % of the patients with IDC. In the ILC group, 8.2 % of the patients needed surgical reinterventions after BCS due to tumor-positive resection margins compared with 3.4 % of the patients with IDC P < 0.0001. Lobular histology was independently associated with a higher mastectomy rate odds ratio 1.91; 95 % confidence interval 1.49–2.44. Among the patients with clinical T2 and T3 disease, BCS was achieved more often when NAC was administered in ILC as well as IDC.

ConclusionThe patients with ILC receiving NAC were less likely to experience a pCR and less likely to undergo BCS than the patients with IDC. With regard to BCS, the impact of NAC for ILC patients was lower than for patients receiving surgery without NAC. However, despite the high number to treating in order to achieve BCS, a small subset of ILC patients, especially cT2 and cT3 patients, still may benefit from NAC.

W. Truin and G. Vugts have contributed equally to this research and should be considered as first author.

Download fulltext PDF



Autor: W. Truin - G. Vugts - R. M. H. Roumen - A. J. G. Maaskant-Braat - G. A. P. Nieuwenhuijzen - M. van der Heiden-van der

Fuente: https://link.springer.com/







Documentos relacionados